Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Trulicity Summary of Product Characteristics (SmPC)

Trulicity® (dulaglutide): Use With Mix and NPH Insulins

Dulaglutide has not been studied in combination with NPH insulins or mixed insulins.

Information from the label

When dulaglutide is added to existing therapy of insulin, a reduction in the dose of insulin may be considered to reduce the risk of hypoglycaemia.1

The use of dulaglutide does not require blood glucose self‑monitoring. Blood glucose self-monitoring is necessary to adjust the dose of insulin, particularly when dulaglutide therapy is started and insulin is reduced. A stepwise approach to insulin dose reduction is recommended.1

References

1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: September 29, 2017

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question